Shikonin circumvents cancer drug resistance by induction of a necroptotic death

Molecular Cancer Therapeutics

Volumn 6, Issue 5, 2007, Pages 1641-1649

  Han, Weidong ^a   Li, Ling ^a   Qiu, Shuang ^a   Lu, Qinghua ^a   Pan, Qiangrong ^a   Gu, Ying ^a   Luo, Jianhong ^a   Hu, Xun ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; NAPHTHOQUINONE; PROTEIN BCL 2; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; SHIKONIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DEATH; CELL MEMBRANE; CELL STRAIN HEK293; CELL STRAIN MCF 7; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MICE; MICE, NUDE; NAPHTHOQUINONES; NECROSIS; NEOPLASM TRANSPLANTATION;

EID: 34250748014     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0511     Document Type: Article

References (37)

1. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92.
2. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
3. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 2003;228:995-1003.
4. Juranka PF, Zastawny RL, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989;3:2583-92.
5. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302.
6. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 2002;1:427-34.
7. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW. Pglycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 2002;9:1266-72.
8. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93:1075-85.
9. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003;10:159-65.
10. Hersey P, Zhang XD. Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 2003;196:9-18.
11. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000;65:95-106.
12. Blagosklonny MV. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 2004;23:2967-75.
13. Chen CH, Chern CL, Lin CC, et al. Involvement of reactive oxygen species, but not mitochondrial permeability transition in the apoptotic induction of human SK-Hep-1 hepatoma cells by shikonin. Planta Med 2003;69:1119-24.
14. Sankawa U, Ebizuka Y, Miyazaki T, Isomura Y, Otsuka H. Antitumor activity of shikonin and its derivatives. Chem Pharm Bull (Tokyo) 1977;25:2392-5.
15. Yoon Y, Kim YO, Lim NY, Jeon WK, Sung HJ. Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line. Planta Med 1999;65:532-5.
16. Chen X, Yang L, Oppenheim JJ, Howard MZ. Cellular pharmacology studies of shikonin derivatives. Phytother Res 2002;16:199-209.
17. Wu Z, Wu L, Li L, Tashiro S, Onodera S, Ikejima T. p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-2 cells. J Pharmacol Sci 2004;94:166-76.
18. Wu Z, Wu LJ, Li LH, Tashiro S, Onodera S, Ikejima T. Shikonin regulates HeLa cell death via caspase-3 activation and blockage of DNA synthesis. J Asian Nat Prod Res 2004;6:155-66.
19. Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005;1:112-9.
20. Godard T, Deslandes E, Lebailly P, et al. Comet assay and DNA flow cytometry analysis of staurosporine-induced apoptosis. Cytometry 1999;36:117-22.
21. Arnoult D, Parone P, Martinou JC, Antonsson B, Estaquier J, Ameisen JC. Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli. J Cell Biol 2002;159:923-9.
22. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004;23:2785-96.
23. Kagawa S, Gu J, Honda T, et al. Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death. Clin Cancer Res 2001;7:1474-80.
24. Benjamin CW, Hiebsch RR, Jones DA. Caspase activation in MCF7 cells responding to etoposide treatment. Mol Pharmacol 1998; 53:446-50.
25. Hansen TM, Smith DJ, Nagley P. Smac/DIABLO is not released from mitochondria during apoptotic signalling in cells deficient in cytochrome c. Cell Death Differ 2006;13:1181-90.
26. Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ 2000;7:102-11.
27. Pan Q, Lu Q, Zhang K, Hu X. Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 2006;58:99-106.
28. Qiangrong P, Wang T, Lu Q, Hu X. Schisandrin B-a novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun 2005;335:406-11.
29. Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Munoz A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2003;2:863-72.
30. Ribas J, Bettayeb K, Ferandin Y, et al. 7-Bromoindirubin-3′-oxime induces caspase-independent cell death. Oncogene 2006;25:6304-18.
31. Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 2000;95:2378-85.
32. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 2002;99:292-8.
33. Johnson WW. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods Find Exp Clin Pharmacol 2002;24:501-14.
34. Bakker M, Renes J, Groenhuijzen A, et al. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines. Int J Cancer 1997;73:362-6.
35. Marcus AI, Peters U, Thomas SL, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem 2005;280:11569-77.
36. Guo XP, Zhang XY, Zhang SD. [Clinical trial on the effects of shikonin mixture on later stage lung cancer]. Zhong Xi Yi Jie He Za Zhi 1991;11:598-9.
37. Yu L, Alva A, Su H, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 2004;304:1500-2.